Purple Biotech (Israel) Top Management
KTOV Stock | ILA 4.40 0.40 8.33% |
Purple Biotech employs about 9 people. The company is managed by 18 executives with a total tenure of roughly 110 years, averaging almost 6.0 years of service per executive, having 0.5 employees per reported executive. Analysis of Purple Biotech's management performance can provide insight into the company performance.
Itzhak Israel CEO Chief Executive Officer & Director |
Gil Efron CEO Deputy Chief Executive Officer, Chief Financial Officer |
Purple |
Purple Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Purple Biotech Workforce Comparison
Purple Biotech is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 17,460. Purple Biotech adds roughly 9.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Purple Biotech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Purple Biotech Price Series Summation is a cross summation of Purple Biotech price series and its benchmark/peer.
Purple Biotech Notable Stakeholders
A Purple Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Purple Biotech often face trade-offs trying to please all of them. Purple Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Purple Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Hadas Reuveni | Founder and Chief Technology Officer of TyrNovo (a subsidiary) | Profile | |
Itzhak Israel | Chief Executive Officer & Director | Profile | |
Gil Efron | Deputy Chief Executive Officer, Chief Financial Officer | Profile | |
Gil BenMenachem | Vice President - Business Development | Profile | |
Steven Steinberg | Independent Director | Profile | |
Arie Weber | Independent Director | Profile | |
Ran Tzror | Independent Director | Profile | |
Simcha Rock | CFO, Director | Profile | |
Ido Agmon | Independent Director | Profile | |
Revital SternRaff | Independent Director | Profile | |
Michael Schickler | Head of Clinical Operations | Profile | |
CPA MBA | Strategic Director | Profile | |
Bertrand Liang | Chief Medical Officer | Profile | |
Yisrael Gewirtz | Internal Auditor | Profile | |
Eric Rowinsky | Chairman of the Board | Profile | |
Gil CPA | Deputy CFO | Profile | |
Isaac Israel | CEO Director | Profile | |
Avraham BenTzvi | General Counsel, Secretary | Profile |
About Purple Biotech Management Performance
The success or failure of an entity such as Purple Biotech often depends on how effective the management is. Purple Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Purple management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Purple management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. KITOV PHARMA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.
Please note, the presentation of Purple Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Purple Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Purple Biotech's management manipulating its earnings.
Purple Biotech Workforce Analysis
Traditionally, organizations such as Purple Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Purple Biotech within its industry.Purple Biotech Manpower Efficiency
Return on Purple Biotech Manpower
Revenue Per Employee | 111.1K | |
Revenue Per Executive | 55.6K | |
Net Loss Per Employee | 650K | |
Net Loss Per Executive | 325K |
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |